Imaging software developer Amicas is going commercial with an online image management service that incorporates its Amicas Web-based PACS and systems integration capabilities (PNN 1/00). The
Imaging software developer Amicas is going commercial with an online image management service that incorporates its Amicas Web-based PACS and systems integration capabilities (PNN 1/00). The Watertown, MA-based company has completed testing of the Amicas package and installed dedicated Web/intranet servers in several hospitals. The goal is to deliver real-time, Internet-standard services that integrate teleradiology, PACS, and electronic records from imaging facilities to physicians online anywhere, according to CEO Hamid Tabatabaie. Amicas service subscribers pay $2 to $4 for capture and unlimited distribution of a patients images. The Amicas.net portal is expected to go live later this year.
© 2000 Miller Freeman, Inc., a United News & Media company.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.